Please provide your email address to receive an email when new articles are posted on . Discontinuation of denosumab is associated with a rapid return to pretreatment BMD levels and an increased risk ...

The researchers found that 6.3, 6.6, and 11.1% of the zoledronate-zoledronate, zoledronate-placebo, and placebo-placebo groups, respectively, had a new morphometric fracture at follow-up. HealthDay ...

Following an infusion of zoledronate acid in low-risk postmenopausal women, fracture risk reduction emerged only 5-10 years later in a placebo-controlled trial. By year 10, those who received a single ...

Please provide your email address to receive an email when new articles are posted on . “The need to establish treatment efficacy in osteopenia has become more pressing, given the clinical trend to ...

Giving zoledronate every 18 months for 6 years reduced the risk of fragility fractures—both vertebral and nonvertebral—in older women with hip bone mineral density indicating osteopenia, a ...

BACKGROUND: Intravenous zoledronate 5 mg annually reduces fracture risk, and 5 mg every 2 years prevents bone loss, but the optimal dosing regimens for these indications are uncertain. METHODS: We ...

To counter the decline in BMD after denosumab treatment is discontinued, osteoporosis patients may be transitioned from denosumab to other anti-resorptives. This report investigates whether a single ...

Women in early menopause treated with zoledronate in just two infusions, 5 years apart, show a significantly reduced risk of sustaining a vertebral fracture and better maintenance of bone mineral ...

This trial compared zoledronate through a drip with ibandronate tablets. The treatment was for bone weakness and bone pain caused by breast cancer that has spread. This trial was supported by Cancer ...

MONTREAL, QUEBEC — Women age 65 years and older who had osteopenia and received an injection of zoledronate every 18 months for 6 years had a 37% lower rate of fractures than those who received ...

WEDNESDAY, Jan. 15, 2025 (HealthDay News) -- For early postmenopausal women, zoledronate administered at baseline and five years is effective for preventing morphometric vertebral fracture, according ...